Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + vorolanib
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Toripalimab + vorolanib is an investigational combination therapy consisting of two agents with complementary mechanisms of action for cancer treatment. Toripalimab is a humanized IgG4 monoclonal antibody that targets programmed death-1 (PD-1), functioning as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor responses. Vorolanib (CM082) is a small molecule multi-target tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor (PDGFR), c-kit, and Flt-3, thereby inhibiting angiogenesis and tumor proliferation. The rationale for combining these drugs lies in the ability of VEGF inhibition to reduce immunosuppression in the tumor microenvironment and potentially overcome resistance to immune checkpoint blockade. This combination has been studied in phase II clinical trials for non-small cell lung cancer (NSCLC) and advanced mucosal melanoma, showing promising antitumor activity with acceptable safety profiles[1][2][3][4].
- Brand names
- Loqtorzi + Fumena
- Other names
- toripalimab plus vorolanibJS001 plus CM082JS-001 plus CM082JS 001 plus CM082
02
Targets
RET (Rearranged during transfection receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)PRKAA1 (AMP-activated protein kinase alpha catalytic subunit isoform alpha-1)FLT3 (Fms related receptor tyrosine kinase 3)CSF1R (Macrophage colony-stimulating factor receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on toripalimab + vorolanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + vorolanib.